Abbott's new leadless pacemaker system meets primary endpoints in pivotal trial

Abbott park, ill., nov. 12, 2021 /prnewswire/ -- abbott (nyse: abt) today announced new, late-breaking data from the global leadless ii ide study evaluating abbott's investigational aveir leadless pacemaker in patients with certain abnormal heart rhythms.
ABT Ratings Summary
Quant
ABT Quant Ranking
Sector
Industry
Quant Rating
Quant Score